These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20356400)

  • 21. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics.
    Asahina A; Kubo N; Umezawa Y; Honda H; Yanaba K; Nakagawa H
    J Dermatol; 2017 Oct; 44(10):1112-1121. PubMed ID: 28493493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psoriasis, lymphoma and etanercept: is there a correlation?
    Miranda LQ; Bressan AL; Rehfeldt FV; Vasconcelos BN; Gripp AC
    An Bras Dermatol; 2012; 87(1):139-41. PubMed ID: 22481665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions.
    Wu KK; Lee MP; Lee EB; Wu JJ
    J Dermatolog Treat; 2020 Jun; 31(4):359-365. PubMed ID: 30900514
    [No Abstract]   [Full Text] [Related]  

  • 24. The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment.
    Ten Bergen LL; Petrovic A; Krogh Aarebrot A; Appel S
    Scand J Immunol; 2020 Oct; 92(4):e12946. PubMed ID: 32697374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preoperative elevated platelet count and thrombocytosis in gynecologic malignancies.
    Menczer J
    Arch Gynecol Obstet; 2017 Jan; 295(1):9-15. PubMed ID: 27714462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk for deep fungal infections during IL-17 and IL-23 inhibitor therapy for psoriasis.
    Lee MP; Wu KK; Lee EB; Wu JJ
    Cutis; 2020 Oct; 106(4):199-205. PubMed ID: 33186421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatments for psoriasis and the risk of malignancy.
    Patel RV; Clark LN; Lebwohl M; Weinberg JM
    J Am Acad Dermatol; 2009 Jun; 60(6):1001-17. PubMed ID: 19344980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis.
    Bronckers IMGJ; Seyger MMB; West DP; Lara-Corrales I; Tollefson M; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Philipp S; Szalai Z; Vleugels RA; Holland K; Murphy R; Baselga E; Cordoro K; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Paller AS;
    JAMA Dermatol; 2017 Nov; 153(11):1147-1157. PubMed ID: 28903160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platelet activation in psoriasis.
    Berrettini M; Parise P; Constantini V; Grasselli S; Nenci GG
    Thromb Haemost; 1985 Apr; 53(2):195-7. PubMed ID: 3161205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Etanercept provides a more physiological approach in the treatment of psoriasis.
    Altomare G; Ayala F; Berardesca E; Chimenti S; Giannetti A; Girolomoni G; Lotti T; Martini P; Peserico A; Guerra AP; Vena GA
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S1-14. PubMed ID: 18837727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reticulated platelets are increased in chronic myeloproliferative disorders, pure erythrocytosis, reactive thrombocytosis and prior to hematopoietic reconstitution after intensive chemotherapy.
    Ryningen A; Apelseth T; Hausken T; Bruserud Ø
    Platelets; 2006 Aug; 17(5):296-302. PubMed ID: 16928601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of thrombocytosis in HIV+ drug users: impact of antiretroviral therapy.
    Miguez-Burbano MJ; Burbano X; Rodriguez A; Lecusay R; Rodriguez N; Shor-Posner G
    Platelets; 2002 May; 13(3):183-5. PubMed ID: 12180501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort.
    Ahlehoff O; Skov L; Gislason G; Gniadecki R; Iversen L; Bryld LE; Lasthein S; Lindhardsen J; Kristensen SL; Torp-Pedersen C; Hansen PR
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1128-34. PubMed ID: 25303139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombocytosis in rheumatoid arthritis.
    Hutchinson RM; Davis P; Jayson MI
    Ann Rheum Dis; 1976 Apr; 35(2):138-42. PubMed ID: 942269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pneumocystis jirovecii pneumonia in a patient with pustular psoriasis with an IL-36RN deficiency treated with infliximab: Case report and review of the literature.
    Podlipnik S; de la Mora L; Alsina M; Mascaró JM
    Australas J Dermatol; 2017 May; 58(2):e44-e47. PubMed ID: 27170513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevated platelet counts and thrombocytosis in erythema nodosum leprosum.
    Rea TH
    Int J Lepr Other Mycobact Dis; 2002 Sep; 70(3):167-73. PubMed ID: 12483964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.
    Asgari MM; Ray GT; Geier JL; Quesenberry CP
    J Am Acad Dermatol; 2017 Apr; 76(4):632-638. PubMed ID: 28162854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Crohn's-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report.
    Smith MK; Pai J; Panaccione R; Beck P; Ferraz JG; Jijon H
    BMC Gastroenterol; 2019 Sep; 19(1):162. PubMed ID: 31488067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ustekinumab: new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients.
    Prescrire Int; 2009 Oct; 18(103):202-4. PubMed ID: 19882785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Verruca vulgaris developing during cyclosporin therapy for psoriasis vulgaris.
    Irimajiri J; Yamamoto T; Kimura K; Yokozeki H; Nishioka K
    J Dermatol; 1998 Oct; 25(10):688-90. PubMed ID: 9830272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.